Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acurx Pharmaceuticals ( (ACXP) ) just unveiled an update.
On June 17, 2025, Acurx Pharmaceuticals entered into a warrant inducement agreement with a holder of existing warrants to purchase an aggregate of 4,445,435 shares of common stock at a reduced exercise price of $0.60 per share, resulting in gross proceeds of approximately $2.67 million. The transaction, expected to close by June 20, 2025, will provide net proceeds of about $2.3 million, which the company intends to use for general corporate and working capital purposes. The agreement also involves issuing new series G-1 and G-2 warrants to purchase additional shares, with a portion of the proceeds allocated to H.C. Wainwright & Co., LLC as fees. These developments are anticipated to impact the company’s financial position and operational capabilities positively.
The most recent analyst rating on (ACXP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company’s research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, such as Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP).
Average Trading Volume: 5,919,182
Technical Sentiment Signal: Hold
Current Market Cap: $16.91M
Learn more about ACXP stock on TipRanks’ Stock Analysis page.